Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. has received a Notice of Compliance from Health Canada for its siRNA medicine REDEMPLO, which is intended to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) when standard therapies are insufficient [1]. Group 1 - The approval of REDEMPLO is significant as it addresses a severe and rare disease characterized by extremely high triglyceride levels, which can range from 10 to 100 times the normal levels [1]. - The medicine is designed to be used as an adjunct to diet, highlighting its role in a comprehensive treatment approach for patients with FCS [1]. - This regulatory approval may open new market opportunities for Arrowhead Pharmaceuticals in the rare disease segment, potentially enhancing its product portfolio and revenue streams [1].